title: Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
abstract: BACKGROUND
  Human herpesvirus type 8 (HHV-8), a gamma herpesvirus associated with Kaposi's sarcoma, has been proposed as a candidate risk factor for prostate cancer (PCa) because of its detection in benign and malignant prostate specimens, and its relation with histologic prostatic inflammation. We investigated the possible relation between pre-diagnostic HHV-8 infection and PCa risk in a case-control study sampled from the placebo arm of the Prostate Cancer Prevention Trial.
  
  
  METHODS
  We defined cases as men with a confirmed diagnosis of PCa after visit 2 (n = 315) and controls as men not diagnosed with PCa during the trial who also had a negative end-of-study prostate biopsy (n = 315). We tested sera from visit 2 for IgG antibodies against HHV-8 using a monoclonal antibody-enhanced immunofluorescence assay against multiple lytic HHV-8 antigens.
  
  
  RESULTS
  The adjusted seroprevalence of HHV-8 infection was 11.6 % for cases and 11.0 % for controls (p = 0.81). No association was observed between HHV-8 seropositivity and PCa risk (OR 1.06, 95 % CI 0.65-1.76).
  
  
  CONCLUSIONS
  Our findings of a null association between HHV-8 seropositivity and PCa risk do not support an association between HHV-8 infection and PCa development, consistent with the general tendency of the epidemiologic literature to date.
authors.affiliation: Division of Public Health Sciences, Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Ave., Box 8100, Rm. 208S, St. Louis, MO, 63110, USA, sutcliffes@wudosis.wustl.edu.
authors.forename: Siobhan
authors.initials: S
authors.lastname: Sutcliffe
authors.forename: Cathee
authors.initials: C
authors.lastname: Till
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Jenkins
authors.forename: Charlotte A
authors.initials: CA
authors.lastname: Gaydos
authors.forename: Phyllis J
authors.initials: PJ
authors.lastname: Goodman
authors.forename: Ashraful M
authors.initials: AM
authors.lastname: Hoque
authors.forename: Ann W
authors.initials: AW
authors.lastname: Hsing
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
authors.forename: William G
authors.initials: WG
authors.lastname: Nelson
authors.forename: Angelo M
authors.initials: AM
authors.lastname: De Marzo
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Platz
mesh_terms: D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D019288:Herpesvirus 8, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010919:Placebos; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000517:prevention & control / Q000821:virology*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000097:blood / Q000517:prevention & control / Q000821:virology*; D016036:Seroepidemiologic Studies
chemical_list: D000914:Antibodies, Viral; D010919:Placebos